PT - JOURNAL ARTICLE AU - Permuth, Jennifer B. AU - Dezsi, Kaleena B. AU - Vyas, Shraddha AU - Ali, Karla N. AU - Basinski, Toni L. AU - Utuama, Ovie A. AU - Denbo, Jason W. AU - Klapman, Jason AU - Dam, Aamir AU - Carballido, Estrella AU - Kim, DaeWon AU - Pimiento, Jose M. AU - Powers, Benjamin D. AU - Choi, Jung W. AU - Chen, Dung-Tsa AU - Teer, Jamie K. AU - Beato, Francisca AU - Ward, Alina AU - Cortizas, Elena M. AU - Whisner, Suzanne Y. AU - Williams, Iverson E. AU - Riner, Andrea N. AU - Tardif, Kenneth AU - Velanovich, Vic AU - Karachristos, Andreas AU - Douglas, Wade G. AU - Legaspi, Adrian AU - Allan, Bassan AU - Meredith, Kenneth AU - Molina-Vega, Manual A. AU - Bao, Philip AU - Julien, Jamii St. AU - Huguet, Kevin L. AU - Green, B. Lee AU - Odedina, Folakemi T. AU - Kumar, Nagi B. AU - Simmons, Vani N. AU - George, Thomas J. AU - Malafa, Mokenge AU - Hodul, Pamela AU - Arnoletti, Juan P. AU - Awad, Ziad T. AU - Bose, Debashish AU - Jiang, Kun AU - Centeno, Barbara A. AU - Gwede, Clement K. AU - Judge, Sarah M. AU - Judge, Andrew R. AU - Jeong, Daniel AU - Bloomston, Mark AU - Merchant, Nipun B. AU - Fleming, Jason B. AU - Trevino, Jose G. AU - , TI - The Florida Pancreas Collaborative Next-Generation Biobank: State-wide Infrastructure to Reduce Disparities and Improve Survival for a Racially and Ethnically Diverse Cohort of Patients with Pancreatic Cancer AID - 10.1101/2020.10.10.20209247 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.10.20209247 4099 - http://medrxiv.org/content/early/2020/10/13/2020.10.10.20209247.short 4100 - http://medrxiv.org/content/early/2020/10/13/2020.10.10.20209247.full AB - Background Well-annotated, high-quality biorepositories provide a valuable platform to support translational research and discovery. However, most biorepositories have poor representation of minority groups, limiting the ability to address cancer health disparities and improve disease outcomes. This report describes the establishment of the Florida Pancreas Collaborative (FPC), the first state-wide prospective longitudinal cohort study and biorepository specifically designed to address the higher burden of pancreatic cancer (PaCa) in African Americans (AA) compared to Non-Hispanic Whites (NHW) and Hispanic/Latinx (H/L).Methods We describe rationale for establishing the FPC and provide an overview of key stakeholders; study eligibility and design; ascertainment and recruitment strategies; and standard operating procedures (SOPs) developed to collect, process, store, and transfer biospecimens, medical images, and data. We also describe the customized cloud-based, secure data management platform built to facilitate recruitment, track study-related workflow, house data, and perform queries. We also present progress to date regarding recruitment and biobanking.Results The FPC consists of multidisciplinary teams from fifteen Florida medical institutions. From March 2019 through August 2020, 350 patients were assessed for study eligibility, 323 met inclusion/exclusion criteria, and 305 (94%) enrolled, including 228 NHW, 30 AA, and 47 H/L, with 94%, 100%, and 94% participation rates, respectively. A high percentage of participants have donated blood (87%), pancreatic tumor tissue (41%), computed tomography scans (76%), and baseline questionnaire data (62%).Conclusions This biorepository addresses a critical gap in PaCa research with the potential to advance basic, clinical, population-based, and translational studies intended to minimize disparities, increase quality of life, and reduce PaCa-related morbidity and mortality.Impact This multi-institutional infrastructure can serve as a prototype for development of similar resources across the country and disease sites.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research in this publication was supported in part by the James and Esther King Biomedical Research Program, Florida Department of Health (Grant #8JK02; awarded to JPB and JGT), and the Tissue Core, Quantitative Imaging Core, the Participant Research, Interventions, and Measurement (PRISM) Core, the Biostatistics and Bioinformatics Shared Resource, and the Pharmacokinetics and Pharmacodynamics Core at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center (P30-CA076292).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by Advarra IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData for this manuscript is not publicly available. It is protected in a secure database by the lead investigator.